| Human immunodeficiency virus I infection
Delstrigo vs Tivicay
Side-by-side clinical, coverage, and cost comparison for human immunodeficiency virus i infection.Deep comparison between: Delstrigo vs Tivicay with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTivicay has a higher rate of injection site reactions vs Delstrigo based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Tivicay but not Delstrigo, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Delstrigo
Tivicay
At A Glance
Oral
Once daily
NNRTI/NRTI combination
Oral
Once daily (or twice daily with certain inducers)
Integrase strand transfer inhibitor (INSTI)
Indications
- Human immunodeficiency virus I infection
- Human immunodeficiency virus I infection
Dosing
Human immunodeficiency virus I infection One tablet orally once daily with or without food in adults and pediatric patients weighing at least 35 kg.
With rifabutin co-administration Take one tablet of DELSTRIGO once daily plus one tablet of doravirine 100 mg (PIFELTRO) approximately 12 hours after the DELSTRIGO dose for the duration of rifabutin co-administration.
Human immunodeficiency virus I infection (treatment-naive or INSTI-naive adults) 50 mg orally once daily, with or without food. Adjust to 50 mg twice daily if coadministered with UGT1A or CYP3A inducers.
Human immunodeficiency virus I infection (INSTI-experienced adults with resistance) 50 mg orally twice daily, with or without food, combined with optimized background therapy.
Human immunodeficiency virus I infection (pediatric patients 3 kg to <6 kg) TIVICAY PD 5 mg orally once daily. Adjust to twice daily if coadministered with UGT1A or CYP3A inducers.
Human immunodeficiency virus I infection (pediatric patients 6 kg to <10 kg) TIVICAY PD 15 mg orally once daily. Adjust to twice daily if coadministered with UGT1A or CYP3A inducers.
Human immunodeficiency virus I infection (pediatric patients 10 kg to <14 kg) TIVICAY PD 20 mg orally once daily. Adjust to twice daily if coadministered with UGT1A or CYP3A inducers.
Human immunodeficiency virus I infection (pediatric patients 14 kg to <20 kg) TIVICAY PD 25 mg orally once daily or TIVICAY tablets 40 mg once daily. Adjust to twice daily if coadministered with UGT1A or CYP3A inducers.
Human immunodeficiency virus I infection (pediatric patients >=20 kg) TIVICAY PD 30 mg orally once daily or TIVICAY tablets 50 mg once daily. Adjust to twice daily if coadministered with UGT1A or CYP3A inducers.
Human immunodeficiency virus I infection (virologically suppressed adults switching to dual therapy) 50 mg orally once daily in combination with rilpivirine 25 mg once daily, with or without food.
Contraindications
- Co-administration with strong CYP3A inducers, including carbamazepine, oxcarbazepine, phenobarbital, phenytoin, enzalutamide, rifampin, rifapentine, mitotane, or St. John's wort
- Previous hypersensitivity reaction to lamivudine
- Hypersensitivity to dolutegravir
- Coadministration with dofetilide
Adverse Reactions
Most common (>=5%) Dizziness, nausea, abnormal dreams
Serious Severe acute exacerbation of hepatitis B, new onset or worsening renal impairment, bone loss and mineralization defects, immune reconstitution syndrome
Postmarketing Stevens-Johnson syndrome/toxic epidermal necrolysis, hepatitis, lactic acidosis, hepatic steatosis, rhabdomyolysis, acute renal failure, Fanconi syndrome, anaphylaxis, anemia
Most common (>=2%, treatment-naive) Insomnia, headache, diarrhea, nausea, fatigue, rash
Serious Hypersensitivity reactions, hepatotoxicity, immune reconstitution syndrome
Postmarketing Sideroblastic anemia, acute liver failure, weight increased, arthralgia, myalgia, anxiety
Pharmacology
DELSTRIGO combines doravirine, an NNRTI that non-competitively inhibits HIV-1 reverse transcriptase; lamivudine, a nucleoside analogue NRTI that terminates HIV-1 DNA chain elongation after phosphorylation to lamivudine triphosphate; and tenofovir disoproxil fumarate, a nucleotide analogue prodrug that, following conversion to tenofovir diphosphate, competitively inhibits HIV-1 reverse transcriptase and causes DNA chain termination.
Dolutegravir is an HIV-1 integrase strand transfer inhibitor that blocks the strand transfer step of retroviral DNA integration essential for HIV replication by binding to the integrase active site.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Delstrigo
- Covered on 5 commercial plans
- PA (4/12) · Step Therapy (0/12) · Qty limit (11/12)
Tivicay
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Delstrigo
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (6/8)
Tivicay
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (4/8)
Humana
Delstrigo
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (3/3)
Tivicay
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$0/fillfill
Delstrigo or Pifeltro Savings CouponCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableGood Days: HIV, AIDS Treatment & Prevention
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
DelstrigoView full Delstrigo profile
TivicayView full Tivicay profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.